Journal of Clinical Oncology, Vol 12, 2043-2050, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

p53 nuclear overexpression: an independent predictor of survival in lymph node--positive colorectal cancer patients

ZS Zeng, AS Sarkis, ZF Zhang, DS Klimstra, E Charytonowicz, JG Guillem, C Cordon-Cardo and AM Cohen
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

PURPOSE: This study was performed to determine the prognostic significance of p53 gene overexpression in a homogeneous group of node- positive colorectal cancer patients. MATERIALS AND METHODS: Paraffin sections from the primary tumors in 107 colorectal cancer patients who had preoperative serum carcinoembryonic antigen (CEA) levels less than five were examined for the expression of p53 nuclear protein by immunohistochemical staining using the monoclonal antibody PAb 1801. The nuclear p53 overexpression was compared with clinicopathologic variables and follow-up data. RESULTS: Positive staining was not observed in normal colorectal mucosal cells. Specific p53 nuclear staining was detected in primary tumor from 50 patients (46.7%). p53 nuclear overexpression was not significantly correlated with patients' sex, age, tumor location, differentiation, T stage, N stage, and lymphatic and/or vascular vessel invasion. With a median follow-up of 61.7 months, 60% of the p53-positive patients have had disease recurrence, versus only 35% of the p53-negative group (P = .02). Forty- two percent of the p53-positive patients died of colorectal cancer compared with 21.1% of the p53-negative patients (P = .03). By multivariate analysis, p53 overexpression was found to be an independent predictor for disease-free and disease-specific survival. CONCLUSION: In node-positive colorectal cancer patients with low preoperative CEA levels, nuclear p53 overexpression as determined by immunohistochemistry on archived tissue is an independent predictor for prognosis.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Ravi, A. J. Jain, R. D. Schulick, V. Pham, T. S. Prouser, H. Allen, E. G. Mayer, H. Yu, D. M. Pardoll, A. Ashkenazi, et al. Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAIL Cancer Res., December 15, 2004; 64(24): 9105 - 9114. [Abstract] [Full Text] [PDF]

				M. M. Garrity, L. J. Burgart, M. R. Mahoney, H. E. Windschitl, M. Salim, M. Wiesenfeld, J. E. Krook, J. C. Michalak, R. M. Goldberg, M. J. O'Connell, et al. Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study J. Clin. Oncol., May 1, 2004; 22(9): 1572 - 1582. [Abstract] [Full Text] [PDF]

				M. Gonen, A. Hummer, A. Zervoudakis, D. Sullivan, Y. Fong, D. Banerjee, D. Klimstra, C. Cordon-Cardo, J. Bertino, and N. Kemeny Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer J. Clin. Oncol., February 1, 2003; 21(3): 406 - 412. [Abstract] [Full Text] [PDF]

				C. J. Allegra, S. Paik, L. H. Colangelo, A. L. Parr, I. Kirsch, G. Kim, P. Klein, P. G. Johnston, N. Wolmark, and H. S. Wieand Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes' B and C Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., January 15, 2003; 21(2): 241 - 250. [Abstract] [Full Text] [PDF]

				A. J. Bilchik, D. T. Nora, S. Saha, R. Turner, D. Wiese, C. Kuo, X. Ye, D. L. Morton, and D. S. B. Hoon The Use of Molecular Profiling of Early Colorectal Cancer to Predict Micrometastases Arch Surg, December 1, 2002; 137(12): 1377 - 1383. [Abstract] [Full Text] [PDF]

				C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al. Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1735 - 1743. [Abstract] [Full Text] [PDF]

				R S Houlston What we could do now: molecular pathology of colorectal cancer Mol. Pathol., August 1, 2001; 54(4): 206 - 214. [Abstract] [Full Text] [PDF]

				N Xeropotamos, A S Skopelitou, C. Batsis, and A M Kappas Heterotopic gastric mucosa together with intestinal metaplasia and moderate dysplasia in the gall bladder: report of two clinically unusual cases with literature review Gut, May 1, 2001; 48(5): 719 - 723. [Abstract] [Full Text] [PDF]

				H. Zhang Evaluation of Four Antibodies in Detecting p53 Protein for Predicting Clinicopathological and Prognostic Significance in Colorectal Adenocarcinoma Clin. Cancer Res., December 1, 1999; 5(12): 4126 - 4132. [Abstract] [Full Text] [PDF]

				E. Mamounas, S. Wieand, N. Wolmark, H. D. Bear, J. N. Atkins, K. Song, J. Jones, and H. Rockette Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04) J. Clin. Oncol., May 1, 1999; 17(5): 1349 - 1349. [Abstract] [Full Text] [PDF]

				S. Tortola, E. Marcuello, I. Gonzalez, G. Reyes, R. Arribas, G. Aiza, F. J. Sancho, M. A. Peinado, and G. Capella p53 and K-ras Gene Mutations Correlate With Tumor Aggressiveness But Are Not of Routine Prognostic Value in Colorectal Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1375 - 1375. [Abstract] [Full Text] [PDF]

				M Ilyas, X-P Hao, K Wilkinson, I P M Tomlinson, A M Abbasi, A Forbes, W F Bodmer, and I C Talbot Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer Gut, September 1, 1998; 43(3): 383 - 387. [Abstract] [Full Text] [PDF]

				V. E. Pricolo, S. D. Finkelstein, K. Hansen, B. F. Cole, and K. I. Bland Mutated p53 Gene Is an Independent Adverse Predictor of Survival in Colon Carcinoma Arch Surg, April 1, 1997; 132(4): 371 - 375. [Abstract] [PDF]

				D. M. Takanishi Jr, I. Angriman, M. L. Yaremko, A. Montag, C. A. Westbrook, and F. Michelassi Chromosome 17p Allelic Loss in Colorectal Carcinoma: Clinical Significance Arch Surg, June 1, 1995; 130(6): 585 - 589. [Abstract] [PDF]